▲ Peaking
Health
🔮 fades ✓
Newly discovered pathway fuels production of cancer-driving proteins
Newly discovered pathway fuels production of cancer-driving proteins
Kras
7 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Kras
This hub groups 7 separate news trends connected to Kras, spanning July 2, 2026 through November 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 54 article observations and 52 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
▲ Peaking
Health
🔮 fades
New Pancreatic Cancer Vaccine Sparked Immune Responses in 99% of Patients
13 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte pancreatic cancer medicine induces lasting tumor responses, according to coverage from STAT.
◼ Archived
Business
🔮 fades ✓
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck pays $400 million up front to lock worldwide rights to a KRAS G12D inhibitor in a deal that could swell to over $2 billion.
◼ Archived
Health
🔮 fades ✓
A breakthrough in pancreatic cancer has experts excited
A new treatment for metastatic pancreatic cancer and KRAS-mutated cancers is generating optimism among experts and patients.
◼ Archived
Business
🔮 fades ✓
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.